Tired of researching and picking single stocks? These 3 metal ETFs offer a simple, diversified way to invest in the critical raw materials powering infrastructure, manufacturing, and new energy technologies — without the risk of individual companies. Metal ETFs are investment tools that hold shares of mining & metals companies or track metal futures contracts. Metals are the foundational raw materials for infrastructure, manufacturing, and many emerging clean-energy technologies. That’s why demand for metals — from copper and iron ore to lithium and rare earths — tends to grow cyclically over time. For investors who want broad exposure to the metals sector without picking individual stocks, metal ETFs offer a simple solution. These funds typically invest in mining firms, metals produce

💬 Global central banks are rushing home with gold, dumping USD reserves, and rebuilding financial sovereignty. Is this the biggest quiet revolution in monetary history? Let’s break it down. $Gold - main 2606(GCmain)$ A silent financial de-Westernization is accelerating across global central banks. France has just repatriated all its gold held in the United States. Poland’s central bank has been the world’s largest gold buyer for two years running. And China is selling U.S. Treasuries while adding gold for 16 straight months. These moves go far beyond traditional asset allocation. Gold is evolving from a commodity reserve into what nations now view as national security infrastructure. In April 2026, the Bank of France confirmed that all French

Looking for defensive growth in a crashing tech market? While most tech stocks are selling off hard, two Canadian under-the-radar winners are holding strong — and even surging. Let’s take a look at the resilient names that are outperforming when it matters most. While Canada’s stock market has held up relatively well in early 2026, supported by energy, materials, and major bank stocks on the Toronto Stock Exchange (TSX), the tech sector has become a heavy drag on the broader market. Amid widespread risk aversion and sharp pullbacks in many high‑flying tech names, two specialized Canadian technology companies have shown remarkable resilience. Instead of following the market downward, they have delivered independent, high‑return performance. $Firan Tec

Who’s winning the oral weight-loss drug race? The GLP-1 weight-loss market is shifting from injectables to oral pills — and it’s still Novo vs. Lilly at the top. Which giant has stronger long-term momentum? Let’s break it down clearly. The weight-loss drug race is moving from the injectable first half to the oral second half. Late last year, the first oral GLP-1 weight-loss drug was approved, and analysts project the market will near $100 billion by 2030. At the table are the same two giants: Denmark’s Novo Nordisk (NVO) and U.S. star Eli Lilly (LLY). In the injectable era, Lilly overtook the market with superior efficacy from tirzepatide (Mounjaro/Zepbound) and aggressive production expansion, capturing 60% of the U.S. market. Now the battlefield has shifted to oral drugs. Can Novo Nordis